Inotify

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Retrieved on: 
Thursday, September 23, 2021
Polyphagia, EUR, Cachexia, Charisma House, Orbit, Therapy, AKT, PWS, Solution, University of Copenhagen Faculty of Health and Medical Sciences, Chronic obstructive pulmonary disease, Novo Nordisk Foundation, BII, Cancer, Patient, Death, Lists of diseases, Physician, Health, Diabetes, AI, Prader–Willi syndrome, DKK, Environment, University, Primate, MVP, Company, Program, Woman, Life, Growth, Fertility, Ovarian follicle, Risk, Science, Burn, Weight gain, Research, Drug development, Obesity, Neptune, Survival, Mark (given name), Inotify, Quality of life, Pharmacotherapy, Rheumatoid arthritis, Chronic kidney disease, Pharmaceutical industry, Risk management, Fine chemical, Medical imaging

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.

BioInnovation Institute Creation House program announces intake of four innovative early stage start-up companies

Retrieved on: 
Thursday, September 23, 2021
Polyphagia, EUR, Cachexia, Charisma House, Orbit, Therapy, AKT, PWS, Solution, University of Copenhagen Faculty of Health and Medical Sciences, Chronic obstructive pulmonary disease, Novo Nordisk Foundation, BII, Cancer, Patient, Death, Lists of diseases, Physician, Health, Diabetes, AI, Prader–Willi syndrome, DKK, Environment, University, Primate, MVP, Company, Program, Woman, Life, Growth, Fertility, Ovarian follicle, Risk, Science, Burn, Weight gain, Research, Drug development, Obesity, Neptune, Survival, Mark (given name), Inotify, Quality of life, Pharmacotherapy, Rheumatoid arthritis, Chronic kidney disease, Health insurance, Pharmaceutical industry, Risk management, Fine chemical, Medical imaging

COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ -- BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program. Creation House consists of a founder-friendly convertible loan of DKK 10M and 18 months incubation at BII with access to labs and office space, business development support, and BII partners. The program allows participants to meet and interact with BII's network of investors, industry partners, alumni and fellow entrepreneurs across its other programs, and is specifically designed to guide companies to a competitive international level and prepare teams for discussions with investors ahead of series A financing rounds.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2021 /PRNewswire/ --BioInnovation Institute (BII), an international commercial foundation with a non-profit objective incubating and accelerating world-class life science research, today announces that four companies have joined its Creation House program.
  • "BII's Creation House program is designed to support start-ups in their journey, and essentially increase the likelihood of success.
  • Creation House is for companies with a solid, initial business plan.
  • Its diverse team brings venture capital, pharma and business expertise together to help early stage companies accelerate to the next level.